Positive Association of US-FLI With the Severity of CAD

NCT06541132 | Recruiting

• 1 other identifier: ChongqingM
• Study Type: observational
• Target: 190
• Locations: 1 country
• Sites: 1

Brief Summary

As a multisystem disease, metabolic dysfunction-associated fatty liver disease (MAFLD) is closely linked to the onset and progression of coronary heart disease (CHD). Ultrasonographic fatty liver indicator (US-FLI) is a semi-quantitative tool for evaluating the degree of hepatic steatosis. Our study aims to explore the relationship between US-FLI based on MAFLD and the severity of CHD.

Conditions

Coronary Artery Disease of Significant Bypass Graft; Metabolic Dysfunction-associated Fatty Liver Disease; SYNTAX Score; Ultrasonography

Keywords

Coronary Artery Disease; Metabolic Dysfunction-associated Fatty Liver Disease; SYNTAX score; Ultrasonography

Outcome Measures

Primary Outcomes (1)

• SYNTAX score

  The complexity of coronary artery disease (CAD) is a predictor of cardiovascular events in patients with \>50 % diameter stenosis as determined by SYNTAX score. The range of US-FLI is 0-8. Fatty liver was diagnosed when US-FLI ≥ 2.

  at baseline

Study Arms (4)

Non-CAD group

non-coronary artery disease group

CAD group

coronary artery disease group

Other: Observational study without human intervention

SS≤22 group

SYNTAX score ≤22

SS≥23 group

SYNTAX score ≥23

Other: Observational study without human intervention

Interventions

Observational study without human intervention OTHER

Observational study without human intervention

CAD group; SS≥23 group

Eligibility Criteria

• Age: 18 Years - 90 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

All research subjects were from the Second Affiliated Hospital of Chongqing Medical University

You may qualify if:

• Patients older than 18 years old
• Patients underwent ICA due to chest pain, chest tightness or other reasons in our hospital from August 2022 to December 2023 were included in our study

You may not qualify if:

• Incomplete clinical data
• previous coronary stent implantation
• no abdominal ultrasound examination
• poor ultrasound image quality
• congenital heart disease
• tumor
• thyroid diseases and infectious diseases

Sponsors & Collaborators

• Chongqing Medical University: lead

Study Sites (1)

The Second Affiliated Hospital of Chongqing Medical University

Chongqing, Chongqing Municipality, 400000, China

RECRUITING

Related Publications (4)

• Eslam M, Newsome PN, Sarin SK, Anstee QM, Targher G, Romero-Gomez M, Zelber-Sagi S, Wai-Sun Wong V, Dufour JF, Schattenberg JM, Kawaguchi T, Arrese M, Valenti L, Shiha G, Tiribelli C, Yki-Jarvinen H, Fan JG, Gronbaek H, Yilmaz Y, Cortez-Pinto H, Oliveira CP, Bedossa P, Adams LA, Zheng MH, Fouad Y, Chan WK, Mendez-Sanchez N, Ahn SH, Castera L, Bugianesi E, Ratziu V, George J. A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. J Hepatol. 2020 Jul;73(1):202-209. doi: 10.1016/j.jhep.2020.03.039. Epub 2020 Apr 8.

  PMID: 32278004 BACKGROUND

• Ballestri S, Nascimbeni F, Baldelli E, Marrazzo A, Romagnoli D, Targher G, Lonardo A. Ultrasonographic fatty liver indicator detects mild steatosis and correlates with metabolic/histological parameters in various liver diseases. Metabolism. 2017 Jul;72:57-65. doi: 10.1016/j.metabol.2017.04.003. Epub 2017 Apr 13.

  PMID: 28641784 BACKGROUND

• Buckley AJ, Thomas EL, Lessan N, Trovato FM, Trovato GM, Taylor-Robinson SD. Non-alcoholic fatty liver disease: Relationship with cardiovascular risk markers and clinical endpoints. Diabetes Res Clin Pract. 2018 Oct;144:144-152. doi: 10.1016/j.diabres.2018.08.011. Epub 2018 Aug 28.

  PMID: 30170074 BACKGROUND

• Liu Z, Que S, Xu J, Peng T. Alanine aminotransferase-old biomarker and new concept: a review. Int J Med Sci. 2014 Jun 26;11(9):925-35. doi: 10.7150/ijms.8951. eCollection 2014.

  PMID: 25013373 BACKGROUND

MeSH Terms

Conditions

Coronary Artery Disease

Interventions

Observation

Condition Hierarchy (Ancestors)

Coronary Disease; Myocardial Ischemia; Heart Diseases; Cardiovascular Diseases; Arteriosclerosis; Arterial Occlusive Diseases; Vascular Diseases

Intervention Hierarchy (Ancestors)

Methods; Investigative Techniques

Central Study Contacts

Tingqiu Wang

CONTACT

+8617815370539; w857683014@163.com

Study Design

• Study Type: observational
• Observational Model: CASE CONTROL
• Time Perspective: CROSS SECTIONAL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Principal Investigator

Study Record Dates

• First Submitted: August 2, 2024
• First Posted: August 7, 2024
• Study Start: July 1, 2022
• Primary Completion: April 28, 2025
• Study Completion: April 28, 2025
• Last Updated: August 21, 2024

Record last verified: 2024-08

Data Sharing

• IPD Sharing: Will not share

Locations

CN (1)